Browse > Article
http://dx.doi.org/10.3345/kjp.2009.52.1.105

The effect of erythropoietin in neonatal rat model of hypoxic-ischemic brain injury  

Kim, Heng-Mi (Department of Pediatrics, College of Medicine, Kyungpook National University)
Choe, Byung-Ho (Department of Pediatrics, College of Medicine, Kyungpook National University)
Kwon, Soon-Hak (Department of Pediatrics, College of Medicine, Kyungpook National University)
Sohn, Yoon-Kyung (Department of Pathology, College of Medicine, Kyungpook National University)
Publication Information
Clinical and Experimental Pediatrics / v.52, no.1, 2009 , pp. 105-110 More about this Journal
Abstract
Purpose : Perinatal asphyxia is an important cause of neonatal mortality and subsequent lifelong neurodevelopmental handicaps. Although many treatment strategies have been tested, there is currently no clinically effective treatment to prevent or reduce the harmful effects of hypoxia and ischemia in humans. Erythropoietin (Epo) has been shown to exert neuroprotective effects in various brain injury models although the exact mechanisms through which Epo functions are not completely understood. This study investigates the effect of Epo on hypoxic-ischemic (HI) brain injury and the possibility that its neuroprotective actions may be associated with iron-mediated metabolism. Methods : HI brain injury was produced in 7-day-old rats by unilateral carotid artery ligation followed by hypoxia with 8% oxygen for 2 h. At the end of HI brain injury, the rats received an intraperitoneal injection of 5,000 units/kg erythropoietin. Random premedication with iron, deferoxamine, iron-deferoxamine, or saline were performed 23 d before HI brain injury. The severity of the brain injury was assessed at 7 d after HI. Results : Single Epo treatment post-HI brain injury reduced the gross and histopathological findings of brain injury. Iron premedication did not increase the incidence or severity of the injury as measured by the damage score. Deferoxamine administration before HI brain injury improved the brain injury as compared to no treatment or Epo treatment. Conclusion : These findings indicate that Epo provides neuroprotective benefits after HI in the developing brain. These findings suggest that Epos neuroprotective actions may involve reducing iron in tissues that mediate the formation of free radicals.
Keywords
Hypoxia; Ischemia; Brain; Erythropoietin; Deferoxamine; Iron;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Alafaci C, Salpietro F, Grasso G, Sfacteria A, Passalacqua M, Morabito A, et al. Effect of recombinant human erythropoietin on cerebral ischemia following experimental subarachnoid hemorrhage. Eur J Pharmacol 2000;406:219-25   DOI   ScienceOn
2 Akisu M, Tuzun S, Arslanoglu S, Yalaz M, Kultursay N. Effect of recombinant human erythropoietin administration on lipid peroxidation and antioxidant enzyme(s) activities in preterm infants. Acta Med Okayama 2001;55:357-62   PUBMED   ScienceOn
3 Kling PJ, Winzerling JJ. Iron status and the treatment of the anemia of prematurity. Clin Perinatol 2002;29:283-94   DOI   ScienceOn
4 Cataltepe O, Vannucci RC, Heitjan DF, Towfighi J. Effect of status epilepticus on hypoxic-ischemic brain damage in the immature rat. Pediatr Res 1995;38:251-7   PUBMED   ScienceOn
5 Feng Y, LeBlanc MH, LeBlanc EB, Parker CC, Fratkin JD, Qian XB, et al. Desmethyl tirilazad improves neurologic function after hypoxic ischemic brain injury in piglets. Crit Care Med 2000;28:1431-8   DOI   ScienceOn
6 Legssyer R, Geisser P, McArdle H, Crichton RR, Ward RJ. Comparison of injectable iron complexes in their ability to iron load tissues and to induce oxidative stress. Biometals 2003;16:425-33   DOI   ScienceOn
7 Liachenko S, Tang P, Xu Y. Deferoxamine Improves Early Postresuscitation Reperfusion After Prolonged Cardiac Arrest in Rats. J Cereb Blood Flow Metab 2003;23:574-81   DOI   ScienceOn
8 Barker DJ, Eriksson JG, Forsen T, Osmond C. Fetal origins of adult disease: strength of effects and biological basis. Int J Epidemiol 2002;31:1235-9   DOI   ScienceOn
9 Blanco LN, Frank L. The formation of alveoli in rat lung during the third and fourth postnatal weeks: effect of hyperoxia, dexamethasone, and deferoxamine. Pediatr Res 1993;34:334-40   PUBMED   ScienceOn
10 Saugstad OD. Bronchopulmonary dysplasia-oxidative stress and antioxidants. Semin Neonatol 2003;8:39-49   DOI   ScienceOn
11 Aydin A, Genc Kurdad, Akhisaroglu M, Yorukoglu Kutsal, Gokmen Necati, Gonullu Erdem. Erythropoietin exerts neuroprotective effect in neonatal rat model of hypoxic-ischemic brain injury. Brain Dev 2003;27:494-8   DOI   ScienceOn
12 Siren AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A 2001;98:4044-9   DOI   ScienceOn
13 Juul S. Recombinant erythropoietin as a neuroprotective treatment : in vitro and in vivo models. Clin Perinatol 2004; 31:129-42   DOI   PUBMED   ScienceOn
14 Buonocore G, Perrone S, Longini M, Paffetti P, Vezzosi P, Gatti MG, et al R. Non protein bound iron as early predictive marker of neonatal brain damage. Brain 2003;126:1224-30   DOI   PUBMED   ScienceOn
15 Catania MA, Marciano MC, Parisi A, Sturiale A, Buemi M, Grasso G, et al. Erythropoietin prevents cognition impairment induced by transient brain ischemia in gerbils. Eur J Pharmacol 2002;437:147-50   DOI   ScienceOn
16 Spandou E, Papadopoulou Z, Soubasi V, Karkavelas G, Simeonidou C, Pazaiti A, et al. Erythropoietin prevents long- term sensorimotor deficits and brain injury following neonatal hypoxia-ischemia in rats. Brain Res 2005;1045:22-30   PUBMED   ScienceOn
17 Buonocore G, Perrone S. Biomarkers of hypoxic brain injury in the neonate. Clin Perinatol 2004;31:107-16   DOI   ScienceOn
18 Weber A, Dzietko M, Berns M, Felderhoff-Mueser U, Heinemann U, Maier RF, et al. Neuronal damage after moderate hypoxia and erythropoietin. Neurobiol Dis 2005;20:594- 600   DOI   ScienceOn
19 Celik M, Gokmen N, Erbayraktar S, Akhisaroglu M, Konakc S, Ulukus C, et al. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci U S A 2002;99:2258-63   DOI   ScienceOn
20 Wiessner C, Allegrini PR, Ekatodramis D, Jewell UR, Stallmach T, Gassmann M. Increased cerebral infarct volumes in polyglobulic mice overexpressing erythropoietin. J Cereb Blood Flow Metab 2001;21:857-64   DOI   ScienceOn
21 Shadid M, Moison R, Steendijk P, Hiltermann L, Berger HM, van Bel F. The effect of antioxidative combination therapy on post hypoxic-ischemic perfusion, metabolism, and electrical activity of the newborn brain. Pediatr Res 1998;44:119-24   DOI   ScienceOn
22 Yu X, Shacka JJ, Eells JB, Suarez-Quian C, Przygodzki RM, Beleslin-Cokic B, et al. Erythropoietin receptor signalling is required for normal brain development. Development 2002; 129:505-16   PUBMED   ScienceOn
23 Juul SE, Yachnis AT, Christensen RD.Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev 1998;52:235-49   DOI   ScienceOn
24 Romsi P, Ronka E, Kiviluoma K, Vainionpaa V, Hirvonen J, Mennander A, et al. Potential neuroprotective benefits of erythropoietin during experimental hypothermic circulatory arrest. J Thorac Cardiovasc Surg 2002;124:714-23   DOI   ScienceOn
25 Heffner JE, Repine JE. Pulmonary strategies of antioxidant defense. Am Rev Respir Dis 1989;140:531-54   ScienceOn
26 Grow J, Barks J. Pathogenesis of hypoxic-ischemic cerebral injury in the term infant : current concepts. Clin Perinatol 2002;29:585-602   DOI   ScienceOn
27 Vamvakas EC, Strauss RG. Meta-analysis of controlled clinical trials studying the efficacy of rHuEPO in reducing blood transfusions in the anemia of prematurity. Transfusion 2001;41:406-15   DOI   ScienceOn